21 Jun
2020

Trump’s Huawei U-turn; Panasonic in huge patent deal; AbbVie wins key Humira thicket case; Time ripe for new IV, says Rivette; Nokia’s patent power; plus much more

Everything we covered on IAM over the last seven days – and all you need to know from the global IP market to set yourself up for the start of another busy week

MONDAY 15th June

A district court in Taiwan’s Taichung City penalised local chipmaker UMC and three employees for misappropriating trade secrets belonging to US DRAM manufacturer Micron. Read more here

Exclusive interview with entrepreneur who has filed two trademark applications at the UK IP Office for the terms BLACK LIVES MATTER and I CAN’T BREATHE. Read more here

The University of California has seen its licensing income stall and that could force it to take a more aggressive line in securing ROI. Read more here

Data shows that medical devices companies enjoy significant success at the ITC, but it is still a relatively under-utilised venue by the sector’s innovators. Read more here

TUESDAY 16th June

The Trump administration is set to alter sanctions on Huawei to clarify that US companies may collaborate with the Chinese company on standards-setting. Read more here

A judge in the Northern District of Illinois has dismissed a lawsuit alleging that AbbVie’s patent thicketing strategy for the world’s best-selling drug Humira contravenes antitrust law. Read more here

Outgoing InterDigital chief licensing officer writes exclusively for IAM on the importance of standards to the enablement of first wireless convergence and then massive expansion. Read more here

WEDNESDAY 17th June

Thousands of patents will change hands when Panasonic finalises the sale of its semiconductor business to Taiwan’s Nuvoton later this month. Read more here

IAM is delighted to announce the launch of IPBC Connect, a month-long series of online events taking place throughout September, with timings to accommodate participants across the world. Read more here

“If you were to put together another fund like IV, I’ll bet that you’ve got opportunities again that we haven’t seen in 10 years,” says Kevin Rivette. Read more here

THURSDAY 18th June

Despite a shutdown which hit China before anywhere else, the country’s patent office has received more applications than at this time last year. Read more here

Japanese pharma giant Takeda continues to divest drug rights to pay down its debt and fund desperately needed innovation. Read more here

The latest Ericsson Mobility Report does not focus on 5G patent licensing, but if you are looking for where the greatest royalty-generation opportunities might be it is essential reading. Read more here

FRIDAY 19th June

After chipmaking spin-out, BYD’s IP team should be prepared for more auto and semiconductor IP risks as the Chinese company seeks to challenge the likes of Infineon. Read more here

A data-driven look at Nokia’s position in the market and how its patent portfolio gives the Finnish giant a host of strong options. Read more here

WIPO rolled out PROOF, its new timestamping solution, in May; and while it has a lot going for it, there are downsides too. Read more here

Acacia’s share price sees big jump after Woodford biotech deal as further details suggest it got the best of the transaction. Read more here

SATURDAY 20th June

Japan is a 5G patent follower, not a leader - and that will shape its IP policy for the new mobile network generation. Read more here

IAM has made all its content relating to the covid-19 pandemic free-to-view. You can access our back catalogue via this link.

Joff Wild

Author | Editor-in-chief

[email protected]

Joff Wild